MDM2 Inhibitor Compounds Selective p53 Reactivation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments are limited in effectively targeting tumors with p53 wildtype function, as MDM2 inhibitors have shown variable efficacy and specificity, and there is a need for compounds that can selectively inhibit the interaction between p53 and MDM2 to reactivate p53 function in cancer cells while sparing normal tissues.
Innovation Solution
Development of compounds, specifically those of Formula I and II, and their pharmaceutically acceptable salts, which inhibit the interaction between p53 and MDM2, thereby activating p53 downstream effector genes, for use in treating various cancers by selectively targeting tumors with p53 wildtype function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If MDM2 inhibitors are used to treat cancer, then p53 function can be reactivated in tumor cells, but the inhibitors show variable efficacy and lack specificity, affecting normal tissues
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features ( Formula I and II with defined R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R25, R26, R27, R28, R29, R30, R31, R32, R33, R34, R35, R36, R37, R38, R39, R40, R41, R42, R43, R44, R45, R46, R47, R48, R49, R50 substituents) that selectively target the MDM2-p53 interaction interface in tumor cells while sparing normal tissues. The compounds are designed to bind specifically to MDM2's p53-binding domain, creating localized selective inhibition of the harmful MDM2-p53 interaction in cancer cells
Solution Approach 2:
The patent applies parameter changes by systematically varying molecular parameters of the inhibitor compounds (substituent types, positions, and configurations in Formulas I and II) to optimize both binding affinity to MDM2 and selectivity for tumor cells. By changing chemical parameters such as the nature of R groups, molecular weight, and structural configuration, the invention achieves compounds with improved efficacy and reduced off-target effects
2Adaptability or versatility
If current cancer treatments are used, then they can address various cancer types, but they are limited in effectively targeting tumors with p53 wildtype function
Solution Approach 1:
The patent applies universality by developing MDM2 inhibitor compounds (Formulas I and II) that can treat multiple cancer types including solid tumors and liquid tumors with p53 wildtype function. The compounds are designed to target the conserved MDM2-p53 interaction mechanism that is relevant across different cancer types, providing a universal therapeutic approach for tumors that retain wildtype p53 but have MDM2-mediated p53 inactivation
Data Source
AI summary
The present invention provides MDM2 inhibitor compounds of Formula I or II, or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.